Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27089326 | 0.80 | DPP4 (0.33) | OPRM1OPRK1DPP4DPP8DPP7 | |
| SCHEMBL27089331 | 0.80 | DPP4 (0.33) | OPRM1OPRK1DPP4DPP8DPP7 | |
| SCHEMBL3512916 | 0.80 | GRM2 (0.36) | DPP4 | |
| SCHEMBL4254372 | 0.80 | GRM2 (0.36) | DPP4 | |
| SCHEMBL6919995 | 0.80 | GRM2 (0.36) | DPP4 | |
| SCHEMBL3012517 | 0.79 | PEPD (0.39) | DPP4DPP8DPP7 | |
| SCHEMBL16400475 | 0.79 | HDAC8 (0.42) | ENPP2 | |
| SCHEMBL16400473 | 0.79 | HDAC8 (0.42) | ENPP2 | |
| SCHEMBL22541605 | 0.77 | ENPP2 (0.33) | ENPP2 | |
| SCHEMBL15129890 | 0.77 | CNR2 (0.41) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022202-B1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-10183025-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2019-01-22 | — | — | US | disclosed |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2018-01-25 | — | — | US | disclosed |
| US-9763957-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | ENPP2 1/4885OPRM1 4449/4885OPRK1 4444/4885 |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | ENPP2 1/4885OPRM1 4449/4885OPRK1 4444/4885 |
| US-10183025-B2 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | ENPP2 1/4885OPRM1 4449/4885OPRK1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.